Diego Novick

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study
    Diego Novick
    Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK
    Psychopharmacology (Berl) 191:1015-22. 2007
  2. pmc Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study
    Jihyung Hong
    Personal Social Services Research Unit, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK
    BMC Psychiatry 12:218. 2012
  3. pmc Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study
    Roberto Brugnoli
    Italian Foundation for the study of Schizophrenia, Rome, Italy
    BMC Psychiatry 12:83. 2012
  4. doi request reprint Which somatic symptoms are associated with an unfavorable course in Asian patients with major depressive disorder?
    Diego Novick
    Global Health Outcomes Research, Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK
    J Affect Disord 149:182-8. 2013
  5. doi request reprint Regional differences in treatment response and three year course of schizophrenia across the world
    Diego Novick
    European Health Outcomes Research, Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    J Psychiatr Res 46:856-64. 2012
  6. doi request reprint Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications
    Diego Novick
    Eli Lilly and Company, Windlesham, UK
    Int Clin Psychopharmacol 27:275-82. 2012
  7. doi request reprint Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study
    Diego Novick
    Health Outcomes Research, Eli Lilly and Company, Windlesham, Surrey, United Kingdom
    J Nerv Ment Dis 200:637-43. 2012
  8. doi request reprint The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs
    D Novick
    European Outcomes Research, Eli Lilly and Co, Surrey, UK
    Pharmacopsychiatry 43:81-5. 2010
  9. doi request reprint Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study
    D Novick
    Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, UK
    Pharmacopsychiatry 42:145-52. 2009
  10. doi request reprint Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia
    Diego Novick
    Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK
    Psychiatry Res 176:109-13. 2010

Detail Information

Publications30

  1. ncbi request reprint Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study
    Diego Novick
    Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK
    Psychopharmacology (Berl) 191:1015-22. 2007
    ..Symptomatic remission is an achievable goal of treatment in patients with schizophrenia...
  2. pmc Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study
    Jihyung Hong
    Personal Social Services Research Unit, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK
    BMC Psychiatry 12:218. 2012
    ..This study aimed to examine the impact of switching from olanzapine to risperidone and vice versa on clinical status and tolerability outcomes in outpatients with schizophrenia in a naturalistic setting...
  3. pmc Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study
    Roberto Brugnoli
    Italian Foundation for the study of Schizophrenia, Rome, Italy
    BMC Psychiatry 12:83. 2012
    ..To identify risk factors for suicide using data from a large, 3-year, multinational follow-up study of schizophrenia (SOHO study)...
  4. doi request reprint Which somatic symptoms are associated with an unfavorable course in Asian patients with major depressive disorder?
    Diego Novick
    Global Health Outcomes Research, Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK
    J Affect Disord 149:182-8. 2013
    ..To investigate the impact of somatic symptoms on the severity and course of depression in Asian patients treated for an acute episode of major depressive disorder (MDD)...
  5. doi request reprint Regional differences in treatment response and three year course of schizophrenia across the world
    Diego Novick
    European Health Outcomes Research, Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    J Psychiatr Res 46:856-64. 2012
    ..These results seem to indicate that patients from Latin America, East Asia, North Africa & Middle East may have a more favorable disease course than patients from European nations...
  6. doi request reprint Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications
    Diego Novick
    Eli Lilly and Company, Windlesham, UK
    Int Clin Psychopharmacol 27:275-82. 2012
    ..In the usual care of outpatients with schizophrenia, treatment continuation among nonadherent patients is longer for depot typicals compared with oral typicals and is accompanied by less hospitalization in the short term...
  7. doi request reprint Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study
    Diego Novick
    Health Outcomes Research, Eli Lilly and Company, Windlesham, Surrey, United Kingdom
    J Nerv Ment Dis 200:637-43. 2012
    ..Olanzapine was found to have the highest monotherapy rate and the longest duration of maintained monotherapy, followed by risperidone, amisulpride, and quetiapine...
  8. doi request reprint The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs
    D Novick
    European Outcomes Research, Eli Lilly and Co, Surrey, UK
    Pharmacopsychiatry 43:81-5. 2010
    ....
  9. doi request reprint Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study
    D Novick
    Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, UK
    Pharmacopsychiatry 42:145-52. 2009
    ..The aim of this study was to compare the outcomes of olanzapine- and valproate-treated patients in an observational study of acute mania with the results of a randomised controlled trial (RCT) assessing the same treatments...
  10. doi request reprint Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia
    Diego Novick
    Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK
    Psychiatry Res 176:109-13. 2010
    ..Also, reversal of some risk factors may improve adherence. Non-adherence is associated with a range of poorer long-term outcomes, with clinical and economic implications...
  11. doi request reprint Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice
    Diego Novick
    Lilly Research Centre, Windlesham, Surrey, UK
    Int Clin Psychopharmacol 25:257-63. 2010
    ..Limitations include differences in study design, patient population, and length of follow-up...
  12. doi request reprint Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study
    Diego Novick
    Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU206PH, UK
    Eur Neuropsychopharmacol 19:542-50. 2009
    ..In conclusion, antipsychotics have different tolerability profiles in terms of the adverse events we monitored. Results should be interpreted conservatively due to the observational study design...
  13. doi request reprint Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study
    Diego Novick
    Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    Schizophr Res 108:223-30. 2009
    ....
  14. doi request reprint Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study
    Diego Novick
    Eli Lilly and Company, Windlesham, Surrey, UK
    Int Clin Psychopharmacol 23:203-8. 2008
    ..Patients who switched to olanzapine experienced a higher weight gain. In conclusion, among patients switching antipsychotic medication, those who switched to olanzapine had better long-term outcomes...
  15. ncbi request reprint Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study
    Diego Novick
    Eli Lilly and Company, Windlesham, Surrey, UK
    Prog Neuropsychopharmacol Biol Psychiatry 29:972-82. 2005
    ..The results should be interpreted conservatively due to the observational design of SOHO...
  16. doi request reprint Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study
    Diego Novick
    Lilly Research Centre, Eli Lilly and Company, Windlesham, Surrey, United Kingdom
    J Clin Psychopharmacol 30:531-40. 2010
    ..Higher baseline clinical severity was associated with EPS development, whereas age, presence of EPS, a higher negative Clinical Global Impression score, and presence of gynecomastia were associated with TD development...
  17. doi request reprint Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study
    Jihyung Hong
    Personal Social Services Research Unit, London School of Economics, London, UK
    Psychiatry Res 190:110-4. 2011
    ..05). In conclusion, non-adherence in bipolar patients was associated with poorer long term clinical outcomes that have economic implications for health-care providers...
  18. doi request reprint Observational study designs for bipolar disorder - what can they tell us about treatment in acute mania?
    Catherine Reed
    Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, GU20 6PH, UK
    Prog Neuropsychopharmacol Biol Psychiatry 33:715-21. 2009
    ..4%) and week 12 (50.5%). The results of this observational study show that treatment for mania is complex with multiple combinations of treatment and frequent switching during an acute episode...
  19. pmc Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity?
    Diego Novick
    Eli Lilly and Company, Windlesham, Surrey, UK
    Patient Prefer Adherence 7:463-70. 2013
    ..The aim of this study is to determine whether the presence of painful physical symptoms (PPS) influences quality of life when taking into account baseline depression severity...
  20. doi request reprint Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia
    Jihyung Hong
    Global Health Outcomes, Eli Lilly and Company, Surrey, UK
    Hum Psychopharmacol 28:438-46. 2013
    ..This study assessed the impact of depot formulations on adherence and treating costs in the naturalistic treatment of previously non-adherent outpatients with schizophrenia...
  21. ncbi request reprint The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain
    Antonio Ciudad
    Clinical Research, Department of Research and Development, Lilly, S A Avda de la Industria, 30, 28108 Alcobendas, Madrid, Spain
    Eur Psychiatry 23:1-7. 2008
    ..This article presents the long-term results in terms of antipsychotic medication maintenance and factors influencing it in a representative sample of patients with schizophrenia recruited in the SOHO study within Spain...
  22. doi request reprint Factors predicting hostility in outpatients with schizophrenia: 36-month results from the SOHO study
    Susana Ochoa
    Research Unit, Parc Sanitari Sant Joan de Deu, CIBERSAM, Barcelona, Spain
    J Nerv Ment Dis 201:464-70. 2013
    ..Extrapyramidal symptoms and tardive dyskinesia, alcohol/substance abuse, cognitive impairment, medication noncompliance, and hospitalizations are predictors of future hostility...
  23. pmc Health care costs before and after diagnosis of depression in patients with unexplained pain: a retrospective cohort study using the United Kingdom General Practice Research Database
    Catherine Reed
    Global Health Outcomes, Eli Lilly and Company, Windlesham, Surrey, UK
    Clinicoecon Outcomes Res 5:37-47. 2013
    ..To assess the impact of pain severity and time to diagnosis of depression on health care costs for primary care patients with pre-existing unexplained pain symptoms who subsequently received a diagnosis of depression...
  24. doi request reprint Costs associated with treatment of chronic low back pain: an analysis of the UK General Practice Research Database
    Jihyung Hong
    Personal Social Services Research Unit, London School of Economics and Political Science, London, United Kingdom
    Spine (Phila Pa 1976) 38:75-82. 2013
    ..Retrospective cohort study of health care costs associated with the treatment of chronic low back pain (CLBP) in the United Kingdom...
  25. ncbi request reprint Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia
    Josep Maria Haro
    Research and Development Unit, Sant Joan de Déu Serveis de Salut Mental, Dr Antoni Pujades 42, 08030 Sant Boi, Barcelona, Spain
    Eur Psychiatry 21:41-7. 2006
    ..The findings from this study should be interpreted conservatively because of its non-randomized observational design...
  26. ncbi request reprint Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study
    Josep Maria Haro
    Sant Joan de Deu SSM, Fundació Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain
    J Clin Psychopharmacol 26:571-8. 2006
    ..The results should be interpreted conservatively because of the observational, nonrandomized study design...
  27. ncbi request reprint Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results
    Josep Maria Haro
    San Joan de Déu Serveis de Salut Mental, Fundació Sant Joan de Déu, Dr Antoni Pujades, 42, 08830 Sant Boi de Llobregat, Barcelona, Spain
    Eur Neuropsychopharmacol 17:235-44. 2007
    ..Antipsychotic maintenance in SOHO was higher than the results of previous randomized studies...
  28. ncbi request reprint Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study
    Martin Knapp
    Centre for the Economics of Mental Health, Institute of Psychiatry, London, UK
    Pharmacoeconomics 26:341-58. 2008
    ..To determine the cost utility of treating schizophrenic patients with olanzapine compared with other antipsychotics in a naturalistic outpatient setting...
  29. doi request reprint Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies
    David Suarez
    Research and Development Unit, Sant Joan de Deu SSM, Fundació Sant Joan de Déu, RETICS RD06 0011 REM TAP Network, Sant Boi, Barcelona, Spain
    J Clin Epidemiol 61:525-30. 2008
    ..Until now, MSMs have not been used to compare the effects of more than two treatments...
  30. ncbi request reprint Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study
    Isabelle Gasquet
    INSERM U669, Maison des Adolescents, Hopital Cochin, AP HP, Paris, France
    Int Clin Psychopharmacol 20:199-205. 2005
    ..The results should be interpreted conservatively due to the observational study design...